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Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regen-
erate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and
in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in
drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes
have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs),
adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-
of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts,
highlighting potential applications and future challenges.Introduction
Heart disease is the most significant cause of morbidity and
mortality in the United States, accounting for more than
800,000 deaths per year on average (equivalent to 1 death every
39 s) (Roger et al., 2011). Each year, nearly 6 million patients
suffer heart failure and 1.25 million patients suffer a new or
recurrent myocardial infarction. Both of these conditions result
in cardiomyocyte death by apoptosis and/or necrosis. Dead
cardiomyocytes are replaced by fibroblasts that divide and
migrate into the damaged area to form scar tissue, leading to
the development of a thin ventricular wall that no longer
contracts properly. Formation of a fibroblastic scar initiates
a series of events that lead to remodeling, hypertrophy, and
ultimately heart failure and further cell death.
The persistence of scar tissue following myocardial infarction
suggests that the heart has little if any capacity to generate new
cardiomyocytes. Shortly after birth, myocardial growth transi-
tions from a hyperplastic to a hypertrophic phase, characterized
by the formation of binucleated cardiomyocytes that withdraw
from the cell cycle (Pasumarthi and Field, 2002). This transition
gave rise to the notion that adult cardiomyocytes are incapable
of proliferating; that is, they are terminally differentiated.
Whereas the majority of adult cardiomyocytes do not prolif-
erate, evidence exists indicating that the adult heart has limited
regenerative capacity, although insufficient to compensate for
the cell death caused by heart disease. Radiocarbon dating of
postmortem cardiac tissue has demonstrated that human adult
cardiomyocytes have a turnover rate of less than 1% per year
and that 40% of the mature adult heart consists of postnatally
generated cardiomyocytes (Bergmann et al., 2009). In addition,
cardiac regeneration without scar tissue has been demonstrated
in model organisms, such as zebrafish, after surgical removal of
up to 20% of the ventricle (Poss et al., 2002). This regeneration16 Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc.occurs through the proliferation and dedifferentiation of cardio-
myocytes (Jopling et al., 2010), and similar regeneration has
been demonstrated in mice, but only within the first week post-
partum (Porrello et al., 2011). Work in adult mice provided
evidence that limited numbers of new cardiomyocytes may be
formed after a myocardial infarction, and lineage tracing experi-
ments suggest these new cells are not derived from existing
cardiomyocytes but rather develop from a progenitor population
(Loffredo et al., 2011), some of which are derived from the
epicardium (Smart et al., 2011). Finally, mononuclear rat cardio-
myocytes have been shown to dedifferentiate and proliferate
in vitro (Zhang et al., 2010). Growth factors from prenatal cardiac
development, such as neuregulin1 (NRG1) (Bersell et al., 2009)
and periostin (POSTN) (Ku¨hn et al., 2007), can induce subpopu-
lations of these cardiomyocytes to reenter the cell cycle in vitro.
However, it is not clear to what extent this phenomenon occurs
in vivo.
In clinical trials, transplantation of noncardiac stem cells such
as skeletal muscle progenitors and bone-marrow-derived cells
has resulted in minor improvement in left ventricular ejection
fraction (LVEF) (Hansson et al., 2009), but also the induction of
arrhythmias (Menasche´ et al., 2008). Because these trans-
planted populations do not generate new cardiomyocytes, the
improvement may be due to paracrine effects that lead to
enhanced vascularization (Gnecchi et al., 2005). The modest
improvement provided by these nonmyocyte populations
coupled with the limited regenerative capacity of the adult heart
has led researchers to investigate new methods for the de novo
derivation of cardiomyocytes. One potential source of these cells
is the adult heart itself, in the form of CPCs, expertly reviewed
elsewhere (Perino et al., 2008). With the discovery of human
embryonic stem cells (hESCs) (Thomson et al., 1998), and
more recently, human induced pluripotent stem cells (hiPSCs)
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focused their efforts on developing strategies to efficiently and
reliably direct stem cell differentiation to the cardiovascular
lineage. Since the initial demonstration that contracting cardio-
myocytes can be generated from both types of human pluripo-
tent stem cells (hPSCs) (Itskovitz-Eldor et al., 2000; Zwi et al.,
2009), the possibility of producing unlimited numbers of human
cardiomyocytes to rebuild the heart has tantalized researchers.
Substantial effort has been made to improve the efficiency and
reproducibility of differentiation, while advancing the aims of
progressing to defined conditions and producing cells on a
clinically relevant scale. Advances in embryology and hPSC
differentiation have offered key insights into the mechanisms of
cardiopoiesis, providing hope that in the future injured hearts
may be repaired through clinical applications of these cells.
A potential alternative source of de novo cardiomyocytes
could result from the ‘‘direct reprogramming’’ of murine cardiac
fibroblasts and other adult cell types into cardiomyocytes using
cardiac-specific transcription factors (Gata4, Mef2c, and Tbx5)
(Ieda et al., 2010). This approach offers the possibility of reprog-
ramming cardiac fibroblasts in vivo for heart regeneration, using
direct delivery of these transcription factors. A variation of the
theme of reprogramming fibroblasts into cardiomyocytes has
been recently described, in which fibroblasts are first partially
reprogrammed using exogenous expression of pluripotency
genes (Oct4, Sox2, and Klf4) (OSK) and then differentiated to
the cardiac lineage (Efe et al., 2011).
Applications of De Novo Cardiomyocytes
One of the main long-term goals of de novo cardiomyocyte
production is to provide a source of donor cardiomyocytes for
cell replacement in damaged hearts. Many forms of heart
disease, including congenital defects and acquired injuries, are
irreversible because they are associated with the loss of nonre-
generative, terminally differentiated cardiomyocytes. Current
therapeutic regimes are palliative, and in the case of end-stage
heart failure, transplantation remains the last resort. However,
transplantation is limited by a severe shortage of both donor cells
and organs. In cases of myocardial infarction, 1 billion cells
would potentially need to be replaced (Laflamme and Murry,
2005), highlighting the need for high-throughput and reproduc-
ible methodologies for de novo cardiomyocyte production. A
major challenge in this field is to establish the most efficient
format for the transplantation of these substantial numbers of
cells. Transplantation of single cell suspensions is easiest, but
engraftment of 3D engineered constructs may be the best
approach for replacing scar tissue with new working myocar-
dium. In addition, concerns over cell survival, immune rejection,
electrical maturation, electrical coupling, arrhythmia, and
whether autologous hiPSCs possess immune privileges (a ques-
tion that has recently been raised with murine iPSCs; Zhao et al.,
2011) still need to be addressed.
A second application lies in novel cardiac drug discovery,
development, and safety testing, a process that is collectively
long, arduous, and expensive, and one which is confounded
by the lack of economical and reliable methods to accurately
mimic the human cardiac physiological response, among other
challenges. Many drug discovery programs have failed because
targets validated in animal models proved unreliable and non-predictive in humans (Denning and Anderson, 2008). The
pharmaceutical industry currently invests approximately
$1.5 billion to successfully develop a candidate drug from
primary screening to market. Among the drugs that ultimately
make it to market, many are later withdrawn due to side effects
associated with electrophysiological alterations of the heart
(Braam et al., 2010). The use of de novo human cardiomyocytes
offers the pharmaceutical industry an invaluable tool for pre-
clinical screening of candidate drugs to treat cardiomyopathy,
arrhythmia, and heart failure, as well as therapeutics to combat
secondary cardiac toxicities. Studies have already demon-
strated that hiPSC-derived cardiomyocytes will react to cardi-
oactive drugs with the expected response, indicating that these
cells can be used in the context of larger predictive toxicology
screens (Davis et al., 2011). The development of new screens
using human cardiomyocytes should reduce the time and cost
of bringing new drugs to market.
A third application is in developmental biology, disease
modeling, and postgenomic personalized medicine. Deriving
hiPSCs from patients with specific cardiac diseases, differenti-
ating them to cardiomyocytes, and then performing electrophys-
iological and molecular analyses may provide a powerful tool
for deciphering the molecular mechanisms of disease (Josowitz
et al., 2011). Studies to date have largely concentrated on reca-
pitulating genetic disease phenotypes in vitro, such as long QT
syndromes (Itzhaki et al., 2011a; Matsa et al., 2011; Moretti
et al., 2010), Timothy syndrome (Yazawa et al., 2011), and
LEOPARD syndrome (Carvajal-Vergara et al., 2010). The possi-
bility of modeling cardiac diseases without a known genetic
element is another exciting prospect. The combination of novel
drug discovery and efficacy testing with cardiomyocytes derived
from patient-specific hiPSCs is a potentially groundbreaking
option for personalized medicine. Additionally, the utility of
pluripotent stem cells as a tool for modeling cardiac develop-
ment is another important application that has recently been
demonstrated for a variety of aneuploid syndromes (Li et al.,
2012).
Cardiomyogenesis
To effectively serve the above applications, efficient and
reproducible generation of cardiovascular cells in vitro must be
developed. Because hPSC differentiation recapitulates embry-
onic development, understanding how the cardiac lineage is
established in the early embryo is essential for differentiation
and development strategies. Understanding cardiogenesis also
allows access to the feedforward gene regulatory networks
that occur during development and ultimately deriving physio-
logically relevant cells. Cardiomyogenesis begins with the
generation of mesoderm via the process of gastrulation, which
has been best studied in the mouse (Arnold and Robertson,
2009; Buckingham et al., 2005; Tam and Loebel, 2007) (Figure 1).
Mesoderm induction begins with NODAL signaling in the prox-
imal epiblast on mouse embryonic day 5 (E5.0), which maintains
BMP4 expression in the extraembryonic ectoderm adjacent to
the epiblast. BMP4 acts by inducing WNT3 expression in the
proximal epiblast. Around E5.5, expression of the WNT antago-
nist Dkk1 and the NODAL antagonists Lefty1 and Cer1moves to
the anterior visceral endoderm, restricting NODAL and WNT
signaling to the posterior epiblast. At E5.75, WNT induces theCell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc. 17
Figure 1. The Mouse as a Model for Human Cardiogenesis
(A) Gastrulation begins with the formation of the primitive streak. Anterior primitive ectoderm cells perform an epithelial to mesenchymal transition (EMT), pass
through the primitive streak, and move laterally between the primitive ectoderm and visceral endoderm.
(B) Cells in themost proximal portion of the primitive streak will form the extraembryonic mesoderm,midprimitive streak cells will form the embryonic tissues such
as heart and blood, and cells of the distal portion of the primitive streak will form the endoderm.
(C) In the case of cardiac progenitors, this midstreak mesoderm progresses laterally, then ventrally, around both sides of the embryo, becoming the lateral plate
mesoderm from which the first heart field (FHF) is derived. The lateral plate mesoderm then delaminates to form the splanchnic mesoderm (on the ventral side),
which forms the second heart field (SHF) and somatic mesoderm (on the dorsal side).
(D) The FHF progenitors form the cardiac crescent, whereas SHF progenitors are found medial to the crescent. The cells of both heart fields then move to the
midline, where the FHF progenitors form a linear heart tube that later contributes to the left ventricle. Cells of the SHF proliferate, migrate, and join with the
cardiomyocytes of the FHF, resulting in the rightward looping of the cardiac tube, a process that culminates in a segmented structure and the formation of cardiac
chambers.
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and Eomes. Subsequently, genes involved in mesoderm
patterning and epithelial-mesenchymal transitions (EMTs),
such as Fgf4 and Fgf8, are expressed in the developing primitive
streak. T and EOMES then induce the expression of MESP1
(Costello et al., 2011; David et al., 2011), which has been
described as the ‘‘master regulator’’ of cardiac progenitor
specification (Bondue et al., 2008).
MESP1 can drive cardiac differentiation via the DKK1-medi-
ated inhibition of WNT signaling (David et al., 2008). It is now
clear that canonical WNT/b-catenin signaling has a biphasic
effect on cardiogenesis (Naito et al., 2006; Ueno et al., 2007).
Downstream of MESP1, cardiogenesis relies on a complex
web of interacting factors and genes, including Tbx5, Nkx2-5,
Mef2c, Gata4, Hand2, Myocd, Isl1, and Foxh1 (Bondue and
Blanpain, 2010). Once cardiogenic mesoderm is specified,
canonical WNT and NOTCH signaling regulate CPC mainte-
nance and differentiation, respectively (Qyang et al., 2007;
Kwon et al., 2009).
The cardiac mesoderm gives rise to the endocardium, the first
heart field (FHF, which forms the atria, left ventricle, and the
nodal conduction system), the secondary heart field (SHF, which
forms the right ventricle, outflow tract, and part of the atria),
and the proepicardial mesenchyme (Buckingham et al., 2005).
The FHF differentiates at the cardiac crescent stage, whereas
the SHF (marked by the expression of Isl1) remains in an undiffer-18 Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc.entiated progenitor state, due to inhibitory WNT signals from the
midline, until incorporation into the heart (Kwon et al., 2007).
Once the cardiac crescent is formed, it is exposed to BMP
signaling from the underlying anterior ectoderm as well as
to BMP, FGF, anticanonical WNT, and noncanonical WNT
signaling from the overlying anterior endoderm (Solloway and
Harvey, 2003). By E8.0, these cells form a primitive heart tube,
consisting of an interior layer of endocardial cells and an exterior
layer of myocardial cells. Once within the heart, FHF and SHF
cells appear to proliferate in response to endocardial-derived
signals, such as neuregulin1 (NRG1), which is driven by NOTCH
signaling (Grego-Bessa et al., 2007), and epicardial signals, such
as retinoic acid, that function via FGF signaling (Lavine et al.,
2005). Further study of the possibility of maintaining and pro-
liferating cardiac progenitors, along with the signaling that
differentiates atrial from ventricular cells and decoupling this
from signaling involved with morphological movement, is of
great interest to the further development of reproducible de
novo cardiomyocyte generation methodologies.
Cardiac Differentiation of hPSCs
The ability to differentiate hPSCs in a directed manner has
progressed considerably in the past 10 years. The most repro-
ducible and efficient strategies involve stage-specific activation
and inhibition of different signaling pathways in defined culture
conditions, recapitulating key steps in cardiac development
Figure 2. Methods for the Differentiation of Human Pluripotent Stem Cells
Three methods for differentiating hPSCs, highlighting commonalities at each of the six steps: pluripotent culture, predifferentiation culture, differentiation format,
and treatment with mesoderm induction factors, cardiac specification factors, and cardiac differentiation factors. (A), Yang et al. (2008) suspension EBs in
StemPro34; (B), Burridge et al. (2007) forced aggregation; (C), Laflamme et al. (2007) monolayer differentiation. Abbreviations: KSR, Knockout Serum
Replacement; FGF2, fibroblast growth factor 2; StemPro34, proprietary medium from Invitrogen; BMP4, bone morphogenic protein 4; VEGFA, vascular
endothelial growth factor A; DKK1, dickkopf homolog 1; SB431542, TGFB/activin/NODAL signaling inhibitor (ALK4,5,7); dorsomorphin, BMP signaling inhibitor
(ALK2,3,6); IWR-1, WNT signaling inhibitor; MEF CM, mouse embryonic fibroblast conditioned hESC medium; IMDM/F12+PVA, IMDM/F12-based media
supplemented with polyvinyl alcohol; RPMI, Roswell Park Memorial Insitute 1640 basal medium; FBS, fetal bovine serum; DMEM, basal media; RPMI+PVA,
RPMI-based media supplemented with polyvinyl alcohol; RPMI-INS, RPMI-based media without insulin; B27, media supplement; NOGGIN, BMP signaling
inhibitor; RAi, retinoic acid signaling inhibitor; LI-APEL, low insulin, Albucult, polyvinyl alcohol, essential lipids media; SCF, stem cell factor (KITLG); LI-BEL, low
insulin, bovine serum albumin, essential lipids media; IWP-4, WNT signaling inhibitor.
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tiation process is very delicate, and the variability in each
individual component of the cardiac differentiation strategy
must be carefully optimized to reliably produce cardiomyocytes.
One of the first directed differentiation methods involved
hESCs cocultured with mouse visceral endoderm-like cells
(END-2) (Mummery et al., 2003), which is relatively inefficient but
hasbeen shown to generatemostly (85%) ventricular-like cardi-
omyocytes (Mummery et al., 2003). This protocol provided early
insight into methods for improving differentiation efficiency,
such as removing fetal bovine serum (FBS), adding L-ascorbic
acid (Passier et al., 2005), and removing insulin between d0 and
d4 (Freund et al., 2008). Two basicmethods for the cardiac differ-
entiation of hPSCs are now widely in use: the formation of
embryoid bodies (EBs), and culturing hPSCs as a monolayer.
Mature versions of each method rely on progressive sequential
inductive environments using growth factors and/or small
molecules. Figure 2 summarizes the principles of the reported
strategies used for cardiomyocyte differentiation from hPSCs.The EB methodology initially involved suspending hPSC
colonies in media containing 20% FBS to form spherical aggre-
gates (Kehat et al., 2001). This technique produces differentiated
cell types of all three germ layers, including cardiomyocytes,
when it is followedby adhesion at a later stage (d4–d7). Although
inefficient, nearly all cell lines (including hiPSCs) form some rhyth-
mically contracting outgrowths in the 5%–15% range (Zwi et al.,
2009). This protocol can be enhanced by adding BMP4 during
d0–d4 (Takei et al., 2009), by the addition of WNT3A during d0–
d2 (Tran et al., 2009), and via small molecule inhibition of WNT
signaling by IWR-1 during d4–d6 (Ren et al., 2011). FBS- and
insulin-free media can support EB cardiac differentiation, the effi-
ciency of which can be enhanced by adding prostaglandin I2 and
the MAP kinase inhibitor SB203580 (Xu et al., 2008), specifically
between d4 and d6 (Gaur et al., 2010). Factors such as WNT3A
(Bu et al., 2009), G-CSF (Shimoji et al., 2010), and L-ascorbic
acid (Cao et al., 2011) can improve cardiac differentiation by
enhancingCPCproliferation,whereas IGF1and IGF2canenhance
hPSC-derived cardiomyocyte proliferation (McDevitt et al., 2005).Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc. 19
Figure 3. Schematic of Current Knowledge of Factors Involved in hPSC Cardiac Differentiation
Factors that influence the progression through each of the six major steps of hPSC cardiomyogenesis: epithelial to mesenchymal transition, mesoderm
differentiation, mesoderm speciation, cardiac specification, cardiomyocyte differentiation, and electricalmaturation. Data shown are derived fromdevelopmental
biology models that have been directly assessed and proved functional in hPSC cardiac differentiation, along with knowledge gained directly from hPSC
differentiation. Below are the markers associated with each of the seven cell types during differentiation; surface markers are marked with an asterisk.
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the Keller Lab (Figure 2A) has proven highly effective for
analyzing growth factor variables and timing during cardiac
differentiation (Kattman et al., 2011; Yang et al., 2008). In this
protocol, EBs are formed in the presence of a low level of
BMP4 and treated with optimized levels of BMP4, fibroblast
growth factor 2 (FGF2), and activin A between d1 and d4, VEGFA
and DKK1 during d4 to d8, and VEGF and FGF2 from d8 onward.
EBs are maintained under hypoxic (5% oxygen) conditions for
12 days. Using this method, approximately 70% of HES2 EBs
spontaneously contract (Yang et al., 2008). Inhibition of TGFB/
activin/NODAL and BMP signaling using the small molecules
SB431542 and dorsomorphin during d3–d5 (Kattman et al.,
2011) or the WNT inhibitor IWR-1 (d4 to 10) (Willems et al.,
2011) has been shown to enhance this system. To overcome
the limitation of EB size heterogeneity, a ‘‘forced aggregation’’
protocol using V- or U-shaped 96-well plates has been em-
ployed (Figure 2B). Initial versions of this system using activin
A and FGF2 produced 23% beating EBs from four different
hESC lines (Burridge et al., 2007). Further developments of
this system, using BMP4 and FGF2 as mesoderm inducers
(Burridge et al., 2011) under hypoxia, increased differentiation
efficiency to 94% of EB beating in a wide range of hESC and
hiPSC lines. Elliot and colleagues (Elliott et al., 2011) demon-
strated a similarly high differentiation efficiency by employing
a forced aggregation protocol that used BMP4, activin A,
WNT3A, KITLG (SCF), and VEGFA for the first 3 days.
The suspension EB and forced aggregation methods are
mature and commonly produce >70% cardiomyocytes, but
these methods are technically complex and time consuming,
which has led to the development of a monolayer-based method
(Figure 2C) (Laflamme et al., 2007), where hPSCs are cultured to20 Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc.a high density, then treatedwith a high dose of activin A, followed
by 4 days of treatment with BMP4; crucially, the media is not
changed during these 4 days to allow the secreted factors to
accumulate. Contracting cells canbe seen at day 12,with apurity
of approximately 30% cardiomyocytes. Improvements to this
system, such as the addition of WNT3A at d0–d1 and DKK1
from d5 to d11, have been demonstrated (Paige et al., 2010).
Further improvements have also been made using a Matrigel
overlay 1 day prior to differentiation to enhance EMT, along
with the removal of insulin and addition of FGF2 from d1 to d5
and DKK1 from d5 to d7 (Uosaki et al., 2011). As with the EB
system, the use of the WNT signaling inhibitors IWR-1 or
IWP-4 has proven effective, in this case when applied from
d3 (Hudson et al., 2011).
One important aspect of these protocols is the required
identification of markers to monitor the efficiency and progress
of differentiation. Although assays that measure the number
of beating EBs and expression of cardiac troponin T (TNNT2)
have proven effective for optimizing differentiation efficiency,
more rigorous definition of the growth factor regime by ana-
lyzing cardiac mesoderm populations, such as the KDR+/
PDGFRA population (Kattman et al., 2011) and a genetically
modified NKX2-5-GFP cell line, to identify the CPC population
(Elliott et al., 2011) has proven effective for optimizing the ratio
of activin A and BMP4 during early differentiation. The further
identification of specific markers expressed during cardiac
differentiation is a high priority.
Collectively, these studies demonstrate that the importance of
exposure of hPSCs to various growth factors at specific times and
in specific doses is essential for directing differentiation from
early mesendoderm via mesoderm toward a more specific
cardiac fate (Figure 3). Data collected from experiments using
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signaling pathways are involved in early cardiac differentiation
of hPSCs—BMP, TGFB/activin/NODAL, WNT, and FGF—with
highly specific temporal windows for effectiveness. There is also
significant evidence that synergistic relationships exist between
growth factors such as BMP4 and FGF2 (Yu et al., 2011). As
with cardiac development in vivo, it is now clear that inhibition of
WNTaswell asBMPandTGFB/activin/NODALduring themiddif-
ferentiation stage has a major role in hPSC cardiomyogenesis
(Ren et al., 2011;Willems et al., 2011; Kattman et al., 2011; Zhang
et al., 2011). Although less well studied, Notch inhibition using
gamma-secretase inhibitor II fromd0 to d8 has also been demon-
strated to affect hPSC cardiac mesoderm induction (Jang et al.,
2008), indicatingpossible involvementof a fifth signalingpathway.
The Developmental Status of hPSC-Derived
Cardiomyocytes
The cardiomyocytes produced to date from hPSCs are largely
immature and most analogous to fetal stages of development;
these hPSC-derived cardiomyocytes exhibit automaticity (spon-
taneous contraction), fetal-type ion channel expression (Beqqali
et al., 2006), fetal-type electrophysiological signals (Davis et al.,
2011), fetal-type gene expression patterns, and fetal-type
physical phenotypes (Cao et al., 2008). Conflicting data exist
regarding the maturity of Ca2+ handling and sarcoplasmic
reticulum status for hPSC-derived cardiomyocytes, although
there is evidence that hPSC-derived cardiomyocytes demon-
strate some mature properties (Itzhaki et al., 2011b). The lack
of maturity of hPSC-derived cardiomyocytes may reduce the
suitability of drug testing but may also have benefits in regards
to regenerative medicine. For example, rodent fetal cardiomyo-
cytes have been demonstrated to have enhanced cell survival
over adult cardiomyocytes after engraftment into the rat heart
(Reinecke et al., 1999), although the issue of automaticity
still remains. Three major subtypes of hPSC-derived cardiomyo-
cytes can be derived that have atrial-, ventricular-, or nodal-like
phenotypes as determined by electrophysiological analysis
of action potentials (APs). Common hPSC differentiation
methodologies create a mixture of these cell types. An enriched
population of nodal-like cells could potentially be used in
the formation of a biological pacemaker, whereas ventricular
types may be used for recovery from myocardial infarction.
Zhu and colleagues demonstrated that GATA6-GFP can mark
nodal-like cells (Zhu et al., 2010) and that inhibition of NRG1b/
ERBB signaling can enhance the population of nodal-like cardi-
omyocytes. Zhang and colleagues have similarly demonstrated
that retinoic acid can increase the proportion of atrial-like cardi-
omyocytes and that retinoic acid inhibition can increase the
proportion of ventricular-like cells (Zhang et al., 2011).
Overcoming Interline Variability in Cardiac
Differentiation of hiPSCs
The diversity in cardiac differentiation capacities between
hESC lines has now been well established (Burridge et al.,
2007; Kattman et al., 2011), and it is possible that hiPSCs may
have more differentiation variability than hESCs. Many factors
likely contribute to this line-to-line variation, including the condi-
tions used to establish and maintain lines, the efficiency of
reprogramming, the cell source used for reprogramming, andlevels of expression of endogenous growth factors. Maintenance
of high-quality hPSCs is essential for efficient and reproducible
differentiation; the level of expression of pluripotency factors
such as POU5F1 (OCT4) and NANOG has been demonstrated
to have a role in mesoderm induction (Yu et al., 2011). The prog-
ress toward a defined culture of hPSCs, although initially focused
on eliminating feeder layers and animal serum products to allow
future clinical translation, has resulted in higher levels of control
over the pluripotent state, which in turn enhances the reproduc-
ibility of differentiation and reduces costs for a future large-scale
culture. hESCs were first derived on a feeder layer of mouse
embryonic fibroblasts (MEFs) in media containing FBS (Thom-
son et al., 1998). Substantial progress has since been made
in controlling hPSC culture, through second-generation media
containing the commercial product knockout serum replace-
ment (KSR) and FGF2 (Amit et al., 2000). In addition, KSR/
FGF2 media conditioned on MEFs have been shown to support
hPSC pluripotency on a Matrigel layer (Xu et al., 2001). Progress
in elucidating a role for high levels of FGF2 along with TGF-b1 to
stimulate the PI3K, MEK/ERK, and SMAD2/3 pathways has
resulted in a third-generation ‘‘defined’’ media in which KSR is
replaced with BSA or human serum albumin (HSA). Despite
some difficulties in implementation (Akopian et al., 2010), several
formulas have achieved widespread use, including XVIVO10
supplemented with FGF2 and TGF-b1 (Li et al., 2005) and the
commercially available mTeSR1 (Ludwig et al., 2006) and Stem-
Pro hESC (Wang et al., 2007). Most recently, Chen and
colleagues achieved a breakthrough in hESC and hiPSC culture
by formulating a fourth-generation, chemically defined medium
(referred to as E8) that contains the growth factors FGF2 and
TGF-b1 while lacking HSA and the antioxidant 2-mercaptoetha-
nol (Chen et al., 2011). This medium, when used in combination
with a recombinant truncated variant of vitronectin, has proved
successful in deriving new hiPSC lines. Although progress
toward a chemically defined culture of hPSCs has been slow
and gradual, this simple and elegant solution has improved the
reproducibility of pluripotent cell culture and overcomes a signif-
icant hurdle in the development of a reproducible cardiac differ-
entiation system.
In addition to culture conditions, the considerable transcript
heterogeneity within hiPSCs of a single cell line (Narsinh et al.,
2011) and the hot spots of aberrant epigenomic reprogramming
(Lister et al., 2011) likely contribute to variability in differentiation
potential. Another source of variability for hiPSCs is cell type of
origin (Martinez-Fernandez et al., 2011). It has been well docu-
mented that certain cell types, such as neural stem cells (Kim
et al., 2009), can be more easily reprogrammed, but whether
this tendency is due to amoremalleable epigenetic state, the ex-
isting expression of a subset of pluripotency-associated genes,
or the activity of epigenetic-state-modifying genes is still unclear.
The retention of epigenetic memory of cell origin (Kim et al.,
2010b) was initially thought to be restricted to low passage
(<15) hiPSCs (Polo et al., 2010), but recent data suggest that
this effect is maintained in later passages as well (Ohi et al.,
2011). This issue becomes more complex given that hPSCs
progressively acquire epigenetic heterogeneity after prolonged
culture, which affects subsequent differentiation (Tanasijevic
et al., 2009), and that different passages of the same cell line
have different cardiac potentials (Paige et al., 2010). AnotherCell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc. 21
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the method used to induce pluripotency influences subsequent
differentiation. It has been demonstrated in mouse iPSCs that
c-Myc-independent (OSK) conditions favor cardiogenic poten-
tial of iPSCs (Martinez-Fernandez et al., 2010), and it has also
been shown that hiPSCs generated under different conditions
have differing cell cycles and DNA replication gene profiles
(Chung et al., 2011). The effects of generating hiPSCs using
defined media, matrices, and small-molecule epigenetic modi-
fiers on subsequent differentiation have yet to be fully explored.
Differences in levels of expression of endogenous signaling cyto-
kines such asNODAL, BMP4, andWNT3A (Kattman et al., 2011;
Paige et al., 2010) clearly contribute to the variability of cardio-
vascular development. Sustained TGFB/activin/NODAL, BMP,
or WNT signaling beyond the cardiac mesoderm step can have
profound inhibitory effects on the generation of contracting car-
diomyocytes within the culture (Kattman et al., 2011). These
differences are not necessarily related to reprogramming, as
they are also observed between different hESC lines. While the
underlying causes of these differences are not known, the devel-
opment of quantitative assays to rapidly measure the levels of
endogenous signaling would enable one to appropriately modify
the induction protocols for each cell line.
Direct Reprogramming and Partial Reprogramming
It is well established that exogenous expression of Myod can
convert murine fibroblasts directly to skeletal muscle (Davis
et al., 1987). This capability was also demonstrated in a variety
of other nonfibroblast cell types (Choi et al., 1990). This process
is comparatively simple because Myod acts as a master regu-
lator of skeletal muscle formation (Wang et al., 2003), whereas
it would appear that no such single gene exists for the direct
reprogramming of cardiomyocytes. It has been demonstrated
that exogenous expression of Gata4, Tbx5, and Baf60c (a
subunit of the Swi/Snf-like BAF chromatin remodeling complex)
was sufficient to reprogram noncardiogenic mesoderm into
beating cardiomyocytes (Takeuchi and Bruneau, 2009). In this
case, Gata4 and Baf60c induce Nkx2-5 expression, which acts
with Gata4 to initiate the cardiac program, with Tbx5 shown to
be required for full cardiomyocyte differentiation. Surprisingly,
none of the expected master regulators of cardiac differentia-
tion, including Mesp1, Nkx2-5, and Isl1, were required for this
reprogramming.
Work on reprogramming to pluripotency has provided new
insight into direct reprogramming, combining high-expression
retroviral vectors with the subtractive assessment strategy
(Takahashi and Yamanaka, 2006). Implementing these
advances, Ieda and colleagues successfully reprogrammed
cardiac fibroblasts into cardiomyocyte-like cells (referred to as
iCMs) via the exogenous expression of Gata4, Mef2c, and
Tbx5 (Ieda et al., 2010) (Figure 4). These investigators began
with a selection of 14 key genes related to cardiac development,
including transcription factors and epigenetic remodeling
factors, and expressed them in cardiac fibroblasts isolated
from neonatal hearts obtained from aMHC-GFP transgenic
mice. Seven days following transduction, 1.7% of cells ex-
pressed GFP. By serial reduction of the 14 factors, it was found
that the optimal combination ofGata4,Mef2c, and Tbx5 resulted
in GFP expression in 20% of the cells. Approximately 6%22 Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc.of cells were positive for both GFP and TNNT2 (a marker of
the sarcomere structure of cardiomyocytes), although the
percentage of TNNT2+ cells increased over an additional
3 weeks of culture. Ieda and colleagues went on to demonstrate
that this reprogramming was not achieved via an ISL1+ CPC or
pluripotent intermediate, but was the result of gradual loss of
fibroblast identity and progressive upregulation of cardiomyo-
cyte-specific genes. iCMs were induced in vitro within 3 days,
although the reprogramming factors were shown to be required
for 2 weeks for stable reprogramming. The iCMs produced
electrophysiological and gene expression profiles similar to
those of fetal cardiomyocytes, although only 30% of the iCMs
(approximately 6% of the total cell number) exhibited sponta-
neous contraction. The GMT cocktail was also shown to be
able to reprogram adult tail-tip dermal fibroblasts to iCMs to
a similar efficiency, albeit with lower expression of TNNT2 and
no demonstration of spontaneous contraction or electrophysio-
logical properties. Transplantation of neonatal cardiac fibro-
blasts into mouse hearts 1 day after reprogramming showed
that reprogramming can be achieved in vivo.
However, the main drawbacks of direct reprogramming are
the low efficiency rates (1 in 20 fibroblasts are successfully
reprogrammed) at present, the use of randomly integrating
retroviruses (which preclude future clinical application), the
experimental complexity (which will make the GMP production
process challenging), and the potential for contamination by
endogenous cardiomyocytes; most importantly, use of this
methodology has not yet been independently verified or
demonstrated in human cells to date. Reprogramming cardiac
fibroblasts into cardiac cells based on isolation of GFP/Thy1+
cardiac fibroblasts from the heart may not necessarily be strin-
gent enough; fluorescence-activated cell sorting (FACS) does
not remove 100% of cardiac cells, and the retroviruses may still
transfect even nondividing cardiac cells. The relationship
between the properties of iCMs and genuine cardiomyocytes
has also not been fully established using more stringent criteria.
Finally, definitive proof of this methodology lies in reprogram-
ming skin fibroblasts (and various other cell types) into cardiac
cells, as can be done reproducibly for the reprogramming of
various adult somatic cell types to pluripotency (Yu et al.,
2007; Takahashi et al., 2007).
Partial Reprogramming
An alternative method to generate differentiated cell types
from fibroblasts is to create partially reprogrammed cells that
can be differentiated to the desired cell type. The potential
advantage of this approach over first establishing iPSCs and
then differentiating them into particular cell lineages is one
of speed. This approach has been used successfully by Efe
and colleagues, who showed that murine fibroblasts can be re-
programmed to cardiomyocytes using the established OSK
combination (with or without c-Myc) in 11–12 days (Efe et al.,
2011) (Figure 4). Using Nebulette-LacZ (a cardiac-muscle-
specificmarker) in transgenic MEFs, they carried out reprogram-
ming under tissue culture conditions designed for cardiac
differentiation rather than iPSC generation. To prevent the cells
from reaching a pluripotent state, an inhibitor of Janus kinase/
signal transducer and activator of transcription (JAK/STAT)
was included in cultures. Cardiomyocytes were efficiently
Figure 4. Schematic of De Novo Cardiomyocyte Generation and Applications
Demonstrating peripheral blood and skin fibroblasts as a cell source, hiPSC derivation and differentiation, direct reprogramming using GMT, and partial re-
programming using OSKM and a full reprogramming inhibitor. Applications in disease modeling, engraftment into the heart, drug discovery, and cardiotoxicity
analysis are shown. Adult heart sources of cardiomyocytes from cardiac progenitor cells and application for in vivo expansion and differentiation are also shown,
as is direct reprogramming of adult cardiac fibroblasts in vivo. Abbreviations: OSKM, Oct4, Sox2, Klf4, c-Myc; JAKi, JAK/STAT inhibitor; GMT, Gata4, Mef2c,
Tbx5; CPC, cardiac progenitor cell.
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and calcium transients. A similar partial reprogramming protocol
has been used by the same lab to generate neural progenitors
(Kim et al., 2011). This technique still needs to be demonstrated
in human cells, wherein an inhibitor suitable for replacing the
pluripotency prevention function of JAK inhibitor would need to
be used due to the differences in mechanisms that control
murine and human pluripotency.
Both the direct reprogramming and partial reprogramming
approaches offer exciting prospects for the future. Both
methods may be entirely suitable to provide the small numbers
of cells required for individualized drug screening and disease
modeling. The direct reprogramming method could potentially
be applied in vivo and would avoid the danger of residual plurip-
otent cells, thereby eliminating the risk of teratoma formation.However, direct in vivo reprogramming could also lead to
ectopic myocardium in scar tissue, which is a known risk factor
for arrhythmias after infarction in humans and requires electrical
ablation by a cardiac elecrophysiologist. Another major concern
is what the in vivo consequence would be for cells that do not
receive the required dose of the GMT cocktail and are only
partially reprogrammed to iCMs. Finally, in both systems, the
problem of viral genomic integration and genomic mutations
due to the use of retroviruses, along with issues of epigenetic
status and scalability, must be overcome.
Cardiomyocyte Purification
Despite considerable progress in improving the efficiency of
cardiac differentiation, the isolation of cardiomyocytes or the
removal of unwanted cell populations may be required.Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc. 23
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involve density gradient centrifugation (Xu et al., 2002) are
unsuitable for large-scale practice and routinely result in only
a 5- to 10-fold enrichment in cardiomyocyte populations (Murry
and Keller, 2008). Genetic selection of cells based on the
expression of a selectable marker driven by a lineage-restricted
promoter such as NKX2-5 (Elliott et al., 2011), MYH6 (Anderson
et al., 2007), MLC2V (Huber et al., 2007), and ISL1 (Bu et al.,
2009) offers the possibility of isolating myocardial precursors
at high purity; when this process is coupled with antibiotic
selection, it is possible to generate cells at greater than 99%
purity. Indeed, it has been demonstrated that an MYH6-
blastocidin hiPSC line can be differentiated using simple
suspension culture and 10% FBS in DMEM to produce
hiPSC-derived cardiomyocytes in commercial quantities
(Ma et al., 2011). The principal drawback of genetic selection
is the necessity (at present) of inserting a selection cassette
into the host genome, which may increase the risk of tumori-
genesis and is therefore unsuitable for clinical practice.
Antibodies to cell surface markers have the advantage of not
requiring genetic modification of stem cell populations, and
therefore may be applicable to all hPSC lines. FACS has the
ability to analyze multiple surface markers simultaneously, and
it has been used to isolate cardiac progenitor populations based
on the expression of the receptor tyrosine kinases KDR (FLK1/
VEGFR2) and PDGFRA (Kattman et al., 2011). Because this pop-
ulation also contains endothelial and smooth muscle popula-
tions, the differentiated progeny represents a mixture of cardio-
myocyte and vascular lineages. The recent identification of
markers expressed specifically on cardiomyocytes, including
EMILIN2 (Van Hoof et al., 2010), SIRPA (Dubois et al., 2011; El-
liott et al., 2011), and VCAM (Elliott et al., 2011; Uosaki et al.,
2011), has made it possible to isolate highly enriched popula-
tions of these cells from hESCs or hiPSCs by FACS or magnetic
bead sorting.
Another nongenetic method for isolating hPSC-derived
cardiomyocytes is based on the use of the mitochondrial dye
tetramethylrhodamine methyl ester perchlorate (TMRM) (Hattori
et al., 2010). Because this dye only functions in cardiomyocytes
with high mitochondrial density, it does not detect the most
immature cells that develop in the cultures (Dubois et al.,
2011). Collectively, these recent discoveries have provided
tools and reagents for the generation of highly enriched popu-
lations of hPSC-derived cardiomyocytes.
Future Directions and Challenges
The field is advancing quickly and we are already witnessing
early applications of hPSCs in modeling human disease, under-
standing human biology, and developing platforms for drug
discovery and predictive toxicology. Challenges remain before
these applications can be widely used to develop regenerative
medicine strategies for treating cardiovascular disease. The
following section highlights some of these challenges.
Currently, monolayer differentiation protocols using hESCs
can produce 2 3 108 enriched cardiomyocytes per T225 flask
(J.D.G., unpublished data). Greater scalability could be achieved
using multilayer tissue culture flasks or culture on suspended
microcarriers. The EB methodology can also be adapted
to high-throughput using flasks with rotating paddles (Amit24 Cell Stem Cell 10, January 6, 2012 ª2012 Elsevier Inc.et al., 2011), or by using a simple suspension culture to pro-
duce hiPSC-derived cardiomyocytes in commercial quantities
(Maet al., 2011). Theeliminationof growth factors from themono-
layer protocol will permit a substantial reduction in costs, and
along with the application of other low-molecular-weight com-
pounds (Willems et al., 2009), will continue to improve scalability.
Although development toward maturity in the electrophysio-
logical properties of hPSC-cardiomyocytes has been demon-
strated over time in culture, better strategies for full development
ofmature intracellular Ca2+ handlingmachinery and ion channels
within cells in vitro must be developed. Techniques that can
induce maturation include the use of small molecules such as
triiodothyronine binding thyroid hormone receptors (Lee et al.,
2010), overexpression or downregulation of specific genes (Ya-
manaka et al., 2008), and extrinsic cues from other noncardiac
cells, including endothelial cells (Kim et al., 2010a). Exercise
via mechanical force (Tulloch et al., 2011) (which will likely be
required for tissue constructs) has also been demonstrated to
enhance maturation. Other important considerations, such clas-
sifying the type of cardiomyocyte (ventricular, atrial, or nodal)
based on AP (Ma et al., 2011) and selecting relevant populations
(either through development of modified differentiation protocols
specific for one cell type [Zhu et al., 2010] or via selection
based on electrophysiology) will need to be addressed. Indeed,
the timing of when subtype fate specification occurs in develop-
ment, how it is regulated, and by what signals is still largely
unknown.
Finally, issues surrounding donor cell death (Nguyen et al.,
2011), tumorigenesis (Cao et al., 2009; Lee et al., 2009), and
prevention of immune rejection (Pearl et al., 2011; Swijnenburg
et al., 2008) remain to be addressed. When engrafted, the new
cardiomyocytes must both induce vascularization to keep the
graft alive as well as electrically couple with the existing cardio-
myocytes and function in synchronization with the existing
heart muscle, or risk generating potentially fatal arrhythmias
(Boudoulas and Hatzopoulos, 2009). In addition, pluripotent
cells remaining in the population might be tumorigenic, and the
ability to detect the presence of these cells with suitable markers
(Ramirez et al., 2011), such as the recently discovered SSEA5
(Tang et al., 2011), will be crucial. To date, engraftment of
hESC-derived cardiomyocytes in a single-cell format has yielded
similar engraftment results to those from other cell types, with
only a 5%–10% improvement in LVEF (Cao et al., 2008; van
Laake et al., 2007), even with the use of ‘‘prosurvival cocktails’’
(Laflamme et al., 2007). Optimal engraftment may require
applying cells as a 3D engineered tissue. For the successful
use of these engineered tissues, the cardiomyocytes are supple-
mentedwith endothelial cells and fibroblasts, as insufficient graft
vascularization can result in poor graft survival (Caspi et al.,
2007). Scaffold-free hESC-derived cardiac patches have been
demonstrated to be successful, along with synthetic polymers,
hydrogels, and natural polymers such as fibrin and type I
collagen (Tulloch et al., 2011). All work thus far with hPSC-
derived cardiomyocytes has been performed in animal models
(mostly in rodents), and it may be difficult for human cardiomyo-
cytes to keep pace with the 450 beats/min required in the
rodent heart (Murry and Keller, 2008). This high beating rate
may also mask arrhythmias. The guinea pig model has a more
suitable heart rate (230–380 beats/min), but at present
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do not exist, requiring the use of immunosuppressants such as
cyclosporin A. Finally, assessment of human-sized cardiac
patches in larger animals such as pigs will be required before
transfer to the clinic is feasible.
In conclusion, our ability to generate cardiomyocytes de novo
has progressed rapidly in the past 5 years, and an increasing
number of potential sources of cells have become viable. The
three major applications of these cardiomyocytes (in regenera-
tive medicine, drug testing, and disease modeling) each have
their own specific requirements for number of cells, speed of
derivation, characterization, and similarity to adult cardiomyo-
cytes. It is likely that a variety of approaches for making cardio-
myocytes will be used in the future, depending on the specific
parameters set by the application. In addition to the plethora of
differentiation methods that have been devised, the core
pathways controlling cardiomyocyte differentiation (BMP,
TGFB/activin/NODAL, and WNT) have been identified. There
are complex questions regarding the application of newly gener-
ated cardiomyocytes still to be answered, including the best
methods for cell delivery and how to ensure a normal physiolog-
ical response of the cells. In addition, many technical issues
remain unresolved. For example, what if cells successfully
engraft and electrically couple, yet do not respond normally to
endogenous stimuli? In addition, the choice of hESCs versus
hiPSCs as the starting material depends on the ultimate use for
which the cells are intended; where ethical considerations are
preeminent, hiPSCs may be the less controversial source.
Certainly, for applications in genetic disease modeling or
personalized therapies, hiPSCs are the obvious choice. By
contrast, the extensive characterization and epigenetic stability
of hESCs may make them more suitable for the large-scale
generation of allogeneic cells for regenerative medicine. Such
questions should not obscure the exciting prospect that, for
the first time, it is possible to envisage overcoming the signifi-
cant hurdles that have blocked the path to successful clinical
application of de novo generated cardiomyocytes.
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